Advances in pharmacotherapy for angiosarcoma
10.16352/j.issn.1001-6325.2024.10.1363
- VernacularTitle:血管肉瘤药物治疗进展
- Author:
Yuping GE
1
;
Ying LIU
;
Lin ZHAO
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院 肿瘤内科,北京 100730
- Keywords:
angiosarcoma;
chemotherapy;
targeted therapy;
immunotherapy
- From:
Basic & Clinical Medicine
2024;44(10):1363-1367
- CountryChina
- Language:Chinese
-
Abstract:
Angiosarcoma(AS)is a rare soft tissue sarcoma originating from vascular or lymphatic endothelial cells,accounting for less than 1% of soft tissue sarcomas.It is most common in skin and surface of soft tissue.The diagno-sis of AS is based on pathology,and the expression of CD31,ERG and CD34 is commonly positive in immuno-his-tochemistry.Staging is performed according to the American Joint Committee on Cancer(AJCC)criteria for soft tis-sue sarcoma.Radical surgery is the primary therapy for locally confined disease.For un-resectable or metastatic an-giosarcoma,chemotherapy is the main treatment method.Targeted therapy and immunotherapy have developed rap-idly in recent years,and the combined therapy of different types of chemotherapy drug has been the focus of optimi-zation in the future.
